First-in-human phase 1 study of RO7119929, an oral TLR7 agonist prodrug, in patients with advanced primary or metastatic liver cancers
RO7119929（一种口服TLR7激动剂前药）在晚期原发性或转移性肝癌患者中的首次人体I期研究
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2025-012783
Yoo, Changhoon; Fabregat-Franco, Carles; Lin, Chia-Chi; Qvortrup, Camilla; Oh, Do-Youn; Yau, Thomas; Kim, Hyung-Don; Castet, Florian; Ponz Sarvise, Mariano; Hsu, Chiun; Rohrberg, Kristoffer Staal; Lichtenegger, Felix Sebastian; Franjkovic, Izolda; Kratochwil, Nicole A; Bessa, Juliana; Rossmann, Eva; Schwalie, Petra C; Rieder, Natascha; Pöschinger, Thomas; Sie, Christina Godfried; Dettling, Steffen; Schlenker, Ramona; Jiang, Tianyi; Dai, Congqi; Yun, Hongying; Hall, Elia; Yeo Te-Ying, Audrey; Hoves, Sabine; Cannarile, Michael A; Schiff, Christina; Sangro, Bruno
